St. Jude Children's Research Hospital officials have named Richard Gilbertson, M.D., Ph.D., director of its Comprehensive Cancer Center and an executive vice president in the organization. St. Jude is home to the first and only National Cancer Institute (NCI)-designated Comprehensive Cancer Center devoted solely to children...
The FDA has approved brentuximab vedotin, brand name Adcetris, for the treatment of HL (Hodgkin lymphoma) and ALCL (systemic anaplastic large cell lymphoma). Adcetris consists of a drug and an antibody - an antibody-drug conjugate - the antibody directs the drug to CD30, a target on lymphoma cells. Adectris was approved under the FDA's accelerated approval program...
Modified Ecstasy May Effectively Treat Leukemia, Lymphoma And Myeloma
8/19/2011
A modified form of Ecstasy (MDMA) may have enormous potential in the treatment of myeloma, lymphoma and leukemia, scientists from the University of Birmingham, England, wrote in the journal Investigational New Drugs. The modified drug is 100 times more powerful as a cancer-busting compound than Ecstacy, which is already known to be effective against over half of white blood cell cancers...
Elacytarabine Combined With Idarubicin Promising For Early Stage AML Patients - Phase II Trial
8/19/2011
Norwegian company, Clavis Pharma ASA, announced promising interim efficacy results from its Phase II clinical investigation with elacytarabine in conjunction with idarubicin in patients with acute myeloid lymphoma (AML) who have failed cytarabine (ara-C)-containing first-course chemotherapy...
Single Flexible Sigmoidoscopy Screening Reduces Colorectal Cancer Incidence And Mortality
8/19/2011
A study published online on yesterday in the Journal of the National Cancer Institute shows, that lower levels of colorectal cancer (CRC) incidence and mortality are linked to a single flexible sigmoidoscopy screening between the ages of 55-64 years...
DARA Receives US FDA Fast Track Designation For KRN5500
8/19/2011
DARA BioSciences, Inc. (NASDAQ: DARA) announced that its investigational drug KRN5500 has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of chemotherapy-induced neuropathic pain in patients with cancer...
Cancer Stem Cells Made, Not Born
8/19/2011
In cancer, tumors aren't uniform: they are more like complex societies, each with a unique balance of cancer cell types playing different roles. Understanding this "social structure" of tumors is critical for treatment decisions in the clinic because different cell types may be sensitive to different drugs...
Generex Subsidiary Antigen Express Provides Update On Phase 2 Breast Cancer Immunotherapy Program
8/19/2011
Generex Biotechnology Corporation (OTCBB: GNBT) announced that the Company's wholly-owned subsidiary Antigen Express, Inc...
New Drug In Early Clinical Testing Offers New Hope For Treatment Of Chronic Leukemia
8/19/2011
While testing a new drug designed to treat chronic leukemia, researchers at Cleveland Clinic discovered new markers that could identify which patients would receive maximum benefit from the treatment. This information was released in the online edition of Blood, a weekly medical journal published by the American Society of Hematology...
Lung Cancer Risk Greater With Certain Gene Combination, Particularly In Light Smokers
8/19/2011
Smokers with variations in two specific genes have a greater risk of smoking more cigarettes, becoming more dependent on nicotine and developing lung cancer, a new study from the Centre for Addiction and Mental Health (CAMH) shows...